Literature DB >> 2590611

Differential effect of aspirin on thromboxane and prostaglandin biosynthesis in man.

J M Ritter1, J R Cockcroft, H S Doktor, J Beacham, S E Barrow.   

Abstract

1. Effects of a single intravenous dose of aspirin (600 mg) on bradykinin-stimulated prostaglandin (PG) and on thromboxane (TX) biosynthesis were determined in nine healthy male volunteers. Plasma concentrations of 6-oxo-PGF1 alpha and 13,14-dihydro-15-oxo-PGF2 alpha were measured in samples obtained during repeated 10 min intravenous infusions of bradykinin before and up to 6 h after the dose of aspirin. TXB2 was measured in serum from blood allowed to clot at 37 degrees C. 2. Aspirin inhibited bradykinin stimulated PG and platelet TX biosynthesis 0.5 h after the dose. Serum TXB2 remained low, whereas PG synthesis recovered within 6 h. 3. Effects of intravenous sodium salicylate (600 mg) were studied identically in eight subjects. Prostanoid biosynthesis was not inhibited. 4. Biosynthesis of prostacyclin and TXA2 under basal conditions was studied in eight subjects by measuring 2,3-dinor-6-oxo-PGF1 alpha and 2,3-dinor-TXB2 in hourly urine samples obtained during and after intravenous infusion of aspirin and, on a separate occasion, of vehicle. 5. Aspirin infusion reduced urinary excretion of both metabolites greater than 90%, but excretion of 2,3-dinor-6-oxo-PGF1 alpha recovered more rapidly than did that of 2,3-dinor-TXB2. 6. We conclude that cyclo-oxygenase is rapidly synthesised in bradykinin-responsive tissues in vivo and that this reflects similarly rapid enzyme biosynthesis in tissues that produce PGI2 under basal conditions.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2590611      PMCID: PMC1380018          DOI: 10.1111/j.1365-2125.1989.tb03544.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  34 in total

1.  Rapid determination of salicylate in biological fluids.

Authors:  P TRINDER
Journal:  Biochem J       Date:  1954-06       Impact factor: 3.857

2.  Inhibition of prostaglandin synthesis in man.

Authors:  M Hamberg
Journal:  Biochem Biophys Res Commun       Date:  1972-11-01       Impact factor: 3.575

3.  Aspirin selectively inhibits prostaglandin production in human platelets.

Authors:  J B Smith; A L Willis
Journal:  Nat New Biol       Date:  1971-06-23

4.  Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs.

Authors:  J R Vane
Journal:  Nat New Biol       Date:  1971-06-23

5.  Indomethacin and aspirin abolish prostaglandin release from the spleen.

Authors:  S H Ferreira; S Moncada; J R Vane
Journal:  Nat New Biol       Date:  1971-06-23

6.  Predominance of locally-produced prostaglandin E2 over prostacyclin in skin incisions in man.

Authors:  J M Ritter; S E Barrow; P L Smith; K M Taylor; C T Dollery
Journal:  Prostaglandins       Date:  1987-12

7.  The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein.

Authors:  G J Roth; P W Majerus
Journal:  J Clin Invest       Date:  1975-09       Impact factor: 14.808

8.  Effect of vasoactive peptides on prostacyclin synthesis in man.

Authors:  S E Barrow; C T Dollery; D J Heavey; N E Hickling; J M Ritter; J Vial
Journal:  Br J Pharmacol       Date:  1986-01       Impact factor: 8.739

9.  Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides.

Authors:  M Hamberg; J Svensson; B Samuelsson
Journal:  Proc Natl Acad Sci U S A       Date:  1975-08       Impact factor: 11.205

10.  Low dose aspirin treatment in late pregnancy differentially inhibits cyclo-oxygenase in maternal platelets.

Authors:  J M Ritter; C Farquhar; A Rodin; M H Thom
Journal:  Prostaglandins       Date:  1987-11
View more
  8 in total

1.  Niacin and biosynthesis of PGD₂by platelet COX-1 in mice and humans.

Authors:  Wen-Liang Song; Jane Stubbe; Emanuela Ricciotti; Naji Alamuddin; Salam Ibrahim; Irene Crichton; Maxwell Prempeh; John A Lawson; Robert L Wilensky; Lars Melholt Rasmussen; Ellen Puré; Garret A FitzGerald
Journal:  J Clin Invest       Date:  2012-03-12       Impact factor: 14.808

2.  Effect of aspirin on vasodilation to bradykinin and substance P in patients with heart failure treated with ACE inhibitor.

Authors:  Andrew P Davie; John J V McMurray
Journal:  Br J Clin Pharmacol       Date:  2002-01       Impact factor: 4.335

Review 3.  Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy.

Authors:  Timothy D Warner; Sven Nylander; Carl Whatling
Journal:  Br J Clin Pharmacol       Date:  2011-10       Impact factor: 4.335

4.  Effects of non-steroidal anti-inflammatory drugs on prostacyclin and thromboxane biosynthesis in patients with mild essential hypertension.

Authors:  P Minuz; S E Barrow; J R Cockcroft; J M Ritter
Journal:  Br J Clin Pharmacol       Date:  1990-10       Impact factor: 4.335

5.  Inhibition of bradykinin-induced vasodilation in human forearm vasculature by icatibant, a potent B2-receptor antagonist.

Authors:  J R Cockcroft; P J Chowienczyk; S E Brett; N Bender; J M Ritter
Journal:  Br J Clin Pharmacol       Date:  1994-10       Impact factor: 4.335

6.  Effects of bradykinin on venous capacitance in health and treated chronic heart failure.

Authors:  Prasad Gunaruwan; Abdul Maher; Lynne Williams; James Sharman; Matthias Schmitt; Ross Campbell; Michael Frenneaux
Journal:  Clin Sci (Lond)       Date:  2009-03       Impact factor: 6.124

7.  Comparative effects of immediate-release and extended-release aspirin on basal and bradykinin-stimulated excretion of thromboxane and prostacyclin metabolites.

Authors:  Jorge L Gamboa; Jessica K Devin; Claudia E Ramirez; Chang Yu; Hui Nian; Rhonda H Lee; Nancy J Brown
Journal:  Pharmacol Res Perspect       Date:  2016-02-23

Review 8.  Anti-platelet drugs and their necessary interaction with endothelial mediators and platelet cyclic nucleotides for therapeutic efficacy.

Authors:  Rebecca B Knowles; Timothy D Warner
Journal:  Pharmacol Ther       Date:  2018-08-04       Impact factor: 12.310

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.